Institutional Repository of Xishuangbanna Tropical Botanical Garden
| Development of a miR-92a delivery system for anti-angiogenesis-based cancer therapy | |
| Ando, H. | |
| 2013 | |
| Source Publication | Journal of Gene Medicine
 |
| ISSN | 1099-498X |
| Volume | 15Issue:1Pages:20-27 |
| Abstract | Background RNA interference has received much attention as a novel therapeutic strategy. MicroRNA (miRNA) appears to be promising as a novel nucleic-acid medicine because it is able to suppress a series of protein expression that relates to a specific event such as angiogenesis. In the present study, we used dicetyl phosphate-tetraethylenepentamine-based polycation liposomes (TEPA-PCL) as a delivery system for miR-92a, one of the miRNAs regulating angiogenesis, and attempted to deliver miR-92a to angiogenic endothelial cells for the development of cancer therapy by anti-angiogenesis. Methods Cholesterol-grafted miR-92a (miR-92a-C) was bound to TEPA-PCL, and the ratio of nitrogen of TEPA-PCL to phosphorus of miR-92a-C (N/P ratio) was optimized. This complex was transfected into human umbilical vein endothelial cells (HUVECs), and the intracellular localization of miR-92a-C was observed under a confocal laser-scanning microscope by the use of fluorescein isothiocyanate-labeled miR-92a-C. After transfection of HUVECs with miR-92a-C/TEPA-PCL, the expression of miR-92a-target proteins (e.g. integrin a5, mitogen-activated protein kinase kinase 4, sphingosine-1-phosphate receptor 1) was examined by western blotting, and a tube formation assay was performed. Results The complex of miR-92a-C with TEPA-PCL was formed and miR-92a-C remained stable with TEPA-PCL at the N/P ratio of 10. After transfection of HUVECs with miR-92a-C complex, miR-92a-C spread into the whole cytoplasm of the cells without any change of cellular morphology, and the expression of several proteins encoded by miR-92a-target genes was suppressed. Furthermore, the capability of forming capillary tubes was impaired in complex-treated HUVECs. Conclusions We have developed a miR-92a delivery system into angiogenic endothelial cells by the use of TEPA-PCL. These results suggest that miR-92a-C/TEPA-PCL is promising for the treatment of tumors via the suppression of angiogenesis. Copyright (c) 2012 John Wiley & Sons, Ltd. |
| Language | 英语 |
| Document Type | 期刊论文 |
| Identifier | https://ir.xtbg.ac.cn/handle/353005/8763 |
| Collection | 公共技术服务中心主要仪器相关文献_激光共聚焦显微镜 |
| Recommended Citation GB/T 7714 | Ando, H.. Development of a miR-92a delivery system for anti-angiogenesis-based cancer therapy[J]. Journal of Gene Medicine,2013,15(1):20-27. |
| APA | Ando, H..(2013).Development of a miR-92a delivery system for anti-angiogenesis-based cancer therapy.Journal of Gene Medicine,15(1),20-27. |
| MLA | Ando, H.."Development of a miR-92a delivery system for anti-angiogenesis-based cancer therapy".Journal of Gene Medicine 15.1(2013):20-27. |
| Files in This Item: | Download All | |||||
| File Name/Size | DocType | Version | Access | License | ||
| Development of a miR（213KB） | 开放获取 | CC BY-NC-SA | View Download | |||
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.
Edit Comment